539 related articles for article (PubMed ID: 20679609)
1. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
Cortes J; Vahdat L; Blum JL; Twelves C; Campone M; Roché H; Bachelot T; Awada A; Paridaens R; Goncalves A; Shuster DE; Wanders J; Fang F; Gurnani R; Richmond E; Cole PE; Ashworth S; Allison MA
J Clin Oncol; 2010 Sep; 28(25):3922-8. PubMed ID: 20679609
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL
J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550
[TBL] [Abstract][Full Text] [Related]
3. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
Scarpace SL
Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
[TBL] [Abstract][Full Text] [Related]
4. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
McBride A; Butler SK
Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.
Spira AI; Iannotti NO; Savin MA; Neubauer M; Gabrail NY; Yanagihara RH; Zang EA; Cole PE; Shuster D; Das A
Clin Lung Cancer; 2012 Jan; 13(1):31-8. PubMed ID: 21862415
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer.
Aogi K; Iwata H; Masuda N; Mukai H; Yoshida M; Rai Y; Taguchi K; Sasaki Y; Takashima S
Ann Oncol; 2012 Jun; 23(6):1441-8. PubMed ID: 21989327
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
Inoue K; Saito T; Okubo K; Kimizuka K; Yamada H; Sakurai T; Ishizuna K; Hata S; Kai T; Kurosumi M
Breast Cancer Res Treat; 2016 Jun; 157(2):295-305. PubMed ID: 27125669
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
McIntyre K; O'Shaughnessy J; Schwartzberg L; Glück S; Berrak E; Song JX; Cox D; Vahdat LT
Breast Cancer Res Treat; 2014 Jul; 146(2):321-8. PubMed ID: 24699910
[TBL] [Abstract][Full Text] [Related]
9. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.
Twelves C; Cortes J; Vahdat LT; Wanders J; Akerele C; Kaufman PA
Clin Breast Cancer; 2010 Apr; 10(2):160-3. PubMed ID: 20299316
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
Park YH; Kim TY; Im YH; Lee KS; Park IH; Sohn J; Lee SH; Im SA; Kim JH; Kim SH; Lee SJ; Koh SJ; Lee KH; Choi YJ; Cho EK; Lee S; Kang SY; Seo JH; Kim SB; Jung KH
Cancer Res Treat; 2017 Apr; 49(2):423-429. PubMed ID: 27488876
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.
Gitlitz BJ; Tsao-Wei DD; Groshen S; Davies A; Koczywas M; Belani CP; Argiris A; Ramalingam S; Vokes EE; Edelman M; Hoffman P; Ballas MS; Liu SV; Gandara DR
J Thorac Oncol; 2012 Mar; 7(3):574-8. PubMed ID: 22198425
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
Hayashida T; Jinno H; Mori K; Sato H; Matsui A; Sakurai T; Hattori H; Takayama S; Wada M; Takahashi M; Seki H; Seki T; Nagayama A; Matsumoto A; Kitagawa Y
BMC Cancer; 2018 Jun; 18(1):701. PubMed ID: 29954362
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
Goel S; Mita AC; Mita M; Rowinsky EK; Chu QS; Wong N; Desjardins C; Fang F; Jansen M; Shuster DE; Mani S; Takimoto CH
Clin Cancer Res; 2009 Jun; 15(12):4207-12. PubMed ID: 19509177
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy, safety and cost of eribulin in patients with metastatic breast cancer].
Paillard MJ; Curtit E; Dobi E; Mansi L; Bazan F; Villanueva C; Chaigneau L; Montcuquet P; Meneveau N; Thiery-Vuillemin A; Nerich V; Pivot X
Bull Cancer; 2015 Sep; 102(9):737-48. PubMed ID: 26022285
[TBL] [Abstract][Full Text] [Related]
15. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.
Yardley DA; Reeves J; Dees EC; Osborne C; Paul D; Ademuyiwa F; Soliman H; Guthrie T; Andersen J; Krekow L; Choksi J; Daniel B; Danso M; Favret A; Oommen S; Brufsky A; Bromund JL; Lin Y; Ibrahim AB; Richards PD
Clin Breast Cancer; 2016 Dec; 16(6):471-479.e1. PubMed ID: 27569274
[TBL] [Abstract][Full Text] [Related]
16. Eribulin mesylate for the treatment of breast cancer.
Cigler T; Vahdat LT
Expert Opin Pharmacother; 2010 Jun; 11(9):1587-93. PubMed ID: 20450446
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.
de Bono JS; Molife LR; Sonpavde G; Maroto JP; Calvo E; Cartwright TH; Loesch DM; Feit K; Das A; Zang EA; Wanders J; Agoulnik S; Petrylak DP
Ann Oncol; 2012 May; 23(5):1241-1249. PubMed ID: 21903605
[TBL] [Abstract][Full Text] [Related]
18. Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital.
Poletti P; Ghilardi V; Livraghi L; Milesi L; Rota Caremoli E; Tondini C
Future Oncol; 2014 Feb; 10(2):233-9. PubMed ID: 24490609
[TBL] [Abstract][Full Text] [Related]
19. Eribulin.
Perry CM
Drugs; 2011 Jul; 71(10):1321-31. PubMed ID: 21770478
[TBL] [Abstract][Full Text] [Related]
20. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Cortes J; O'Shaughnessy J; Loesch D; Blum JL; Vahdat LT; Petrakova K; Chollet P; Manikas A; Diéras V; Delozier T; Vladimirov V; Cardoso F; Koh H; Bougnoux P; Dutcus CE; Seegobin S; Mir D; Meneses N; Wanders J; Twelves C;
Lancet; 2011 Mar; 377(9769):914-23. PubMed ID: 21376385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
